Hospira Launches Oxaliplatin Injection In US

Hospira has reported the US Food and Drug Administration’s approval and launch of oxaliplatin injection in the US. The medication is a generic version of Sanofi-Aventis’ Eloxatin.

Hospira’s oxaliplatin injection is one of the generic versions of this drug to come in solution form. Oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor, and in the treatment of advanced colorectal cancer.

The company said that it will initially offer oxaliplatin injection in 50mg and 100mg single-use vials.

Sue Hazelwood, vice president and general manager of alternate site at Hospira, said: Hospira’s launch of oxaliplatin injection in solution form gives our customers a generic alternative of this critical medication in the formulation they seek. This is another example of Hospira’s dedication to providing high-quality products that will reduce costs in the oncology space.